Antibody therapies are increasingly central to modern medicine, prompting a growing regulatory focus on specificity profiling to ensure safety and minimize off-target effects. This need is especially urgent for next-generation formats such as synthetic and AI-based de novo antibodies, which are developed without animal immunization and therefore lack stringent counterselection, increasing the risk of unintended interactions.

ABscope introduces a unique, cell-based platform for specificity profiling that is both physiologically relevant and scalable—unlike current specificity assays, which are often limited in throughput and applicability. By enabling early-stage screening of multiple biotherapeutic candidates in a human-relevant context, ABscope not only improves safety assessment but also helps guide preclinical development decisions, supporting more efficient and informed therapeutic pipelines.